Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma
NCT ID: NCT01715961
Last Updated: 2016-10-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
98 participants
INTERVENTIONAL
2012-01-31
2016-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project
NCT06156774
Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma
NCT06744075
Treatment of Localized Low Grade Lymphomas
NCT00536458
Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS
NCT02339805
Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)
NCT03104478
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
anthropometric measurement
The muscle area assessed by CT scan imaging at a lumbar vertebral landmark (L3) at the time of diagnosis, at the end of treatment, at 12 and 18 months
* anthropometric measures (weight, height, BMI, brachial and calf circumference) and MNA (mini nutritional assessment)
* albuminemia, transthyretin, orosomucoid, CRP
* functional test to attest the muscular strength: hand grip test, unipodal test, up and go test
* hematological and non-hematological chemotherapy toxicities of cycle 1 and cycle 2
* OS and PFS at 18 and 24 months
* GCB and ABC phenotypes determined by immunohistochemistry and transcriptome analysis
anthropometric measurement
To attest the muscular strength: hand grip test, balance test, up and go test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
anthropometric measurement
To attest the muscular strength: hand grip test, balance test, up and go test
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* DLBCL, grade IIIB follicular lymphoma or histologically proven transformed low grade lymphoma
* Whatever the IPI score and the performance status
* Treated by Rituximab-CHOP or Rituximab-mini-CHOP
* CT scan imaging performed one month or less before inclusion
* Signed informed consent
Exclusion Criteria
* Positivity for HCV, HBV and HIV
* Anthracycline contra-indication
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Henri Becquerel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fabrice JARDIN, MD;PhD
Role: STUDY_DIRECTOR
Centre Henri Becquerel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Henri Becquerel
Rouen, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHB 11-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.